403 related articles for article (PubMed ID: 18390906)
1. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol.
Ross HR; Napier I; Connor M
J Biol Chem; 2008 Jun; 283(23):16124-34. PubMed ID: 18390906
[TBL] [Abstract][Full Text] [Related]
2. Modulation of Recombinant Human T-Type Calcium Channels by Δ
Mirlohi S; Bladen C; Santiago M; Connor M
Cannabis Cannabinoid Res; 2022 Feb; 7(1):34-45. PubMed ID: 33998881
[No Abstract] [Full Text] [Related]
3. A Critical Review of the Role of the Cannabinoid Compounds Δ
Jones É; Vlachou S
Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of recombinant Ca(v)3.1 (alpha(1G)) T-type calcium channels by the antipsychotic drug clozapine.
Choi KH; Rhim H
Eur J Pharmacol; 2010 Jan; 626(2-3):123-30. PubMed ID: 19782679
[TBL] [Abstract][Full Text] [Related]
5. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
6. Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure.
Miller S; Daily L; Leishman E; Bradshaw H; Straiker A
Invest Ophthalmol Vis Sci; 2018 Dec; 59(15):5904-5911. PubMed ID: 30550613
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of cannabidiol on voltage-dependent sodium currents.
Ghovanloo MR; Shuart NG; Mezeyova J; Dean RA; Ruben PC; Goodchild SJ
J Biol Chem; 2018 Oct; 293(43):16546-16558. PubMed ID: 30219789
[No Abstract] [Full Text] [Related]
8. Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine.
Ross HR; Gilmore AJ; Connor M
Br J Pharmacol; 2009 Mar; 156(5):740-50. PubMed ID: 19226289
[TBL] [Abstract][Full Text] [Related]
9. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
10. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
11. Psychotropic and nonpsychotropic cannabis derivatives inhibit human 5-HT(3A) receptors through a receptor desensitization-dependent mechanism.
Xiong W; Koo BN; Morton R; Zhang L
Neuroscience; 2011 Jun; 184():28-37. PubMed ID: 21477640
[TBL] [Abstract][Full Text] [Related]
12. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats.
Parker LA; Burton P; Sorge RE; Yakiwchuk C; Mechoulam R
Psychopharmacology (Berl); 2004 Sep; 175(3):360-6. PubMed ID: 15138755
[TBL] [Abstract][Full Text] [Related]
13. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW
Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination.
Linher-Melville K; Zhu YF; Sidhu J; Parzei N; Shahid A; Seesankar G; Ma D; Wang Z; Zacal N; Sharma M; Parihar V; Zacharias R; Singh G
PLoS One; 2020; 15(6):e0234176. PubMed ID: 32497151
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
[TBL] [Abstract][Full Text] [Related]
17. Δ
Silveira MM; Adams WK; Morena M; Hill MN; Winstanley CA
J Psychiatry Neurosci; 2017 Mar; 42(2):131-138. PubMed ID: 28245177
[TBL] [Abstract][Full Text] [Related]
18. Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model.
Mitchell VA; Harley J; Casey SL; Vaughan AC; Winters BL; Vaughan CW
Neuropharmacology; 2021 May; 189():108529. PubMed ID: 33741405
[TBL] [Abstract][Full Text] [Related]
19. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.
Dos Santos RG; Hallak JEC; Crippa JAS
Adv Exp Med Biol; 2021; 1264():29-45. PubMed ID: 33332002
[TBL] [Abstract][Full Text] [Related]
20. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol.
Vann RE; Gamage TF; Warner JA; Marshall EM; Taylor NL; Martin BR; Wiley JL
Drug Alcohol Depend; 2008 Apr; 94(1-3):191-8. PubMed ID: 18206320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
